Provided by Tiger Trade Technology Pte. Ltd.

Therapeutics

4.46
-0.0650-1.44%
Volume:215.05K
Turnover:966.61K
Market Cap:139.40M
PE:-1.08
High:4.60
Open:4.53
Low:4.42
Close:4.52
52wk High:50.40
52wk Low:4.42
Shares:31.29M
Float Shares:18.39M
Volume Ratio:1.02
T/O Rate:1.17%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.1300
EPS(LYR):-2.8503
ROE:-59.21%
ROA:-37.36%
PB:0.64
PE(LYR):-1.56

Loading ...

Dianthus Therapeutics to Participate in Three Investor Conferences During September

GlobeNewswire
·
Sep 01

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

GlobeNewswire
·
Sep 01

Press Release: Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer

Dow Jones
·
Sep 01

Tenax Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

GlobeNewswire
·
Sep 01

Ceryvyn Therapeutics Plans New Options Issue to Bolster Capital

TIPRANKS
·
Sep 01

Alterity Therapeutics Seeks ASX Quotation for New Ordinary Shares

TIPRANKS
·
Sep 01

Major Insider Move at CAMP4 Therapeutics Raises Investor Eyebrows

TIPRANKS
·
Sep 01

Rakovina Therapeutics Narrows Q2 Loss as AI-Focused Cancer Pipeline Advances

TIPRANKS
·
Sep 01

AN2 Therapeutics presents clinical data supporting development of Epetraborole

TIPRANKS
·
Sep 01

Rakovina Therapeutics Closes Upsized $1.99 Million Private Placement to Advance AI-Driven Cancer Pipeline

TIPRANKS
·
Sep 01

Tenax Therapeutics Cut to Neutral from Buy by Guggenheim

Dow Jones
·
Aug 31

Cadrenal Therapeutics advances CAD-1005 Phase 3 pathway

TIPRANKS
·
Aug 31

Allogene Therapeutics Announces Participation in September Investor Conference

GlobeNewswire
·
Aug 31

Press Release: Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer

Dow Jones
·
Aug 31

Ocumension Therapeutics Enrolls First Patient in Dry Eye Drug Study

MT Newswires Live
·
Aug 31

Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Thrombocytopenia

GlobeNewswire
·
Aug 31

Chemomab Therapeutics to Present at H.C. Wainwright 28th Annual Global Investor Conference

GlobeNewswire
·
Aug 31

Kazia Therapeutics Unveils New Investor-Focused Website

TIPRANKS
·
Aug 31

Kazia Therapeutics Secures $40 Million U.S. Offering to Accelerate Paxalisib Oncology Program

TIPRANKS
·
Aug 31

Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences

GlobeNewswire
·
Aug 31